he deal size was increased to $175M in common stock and warrants from $150M. Morgan Stanley, Leerink, Cantor Fitzgerald, Oppenheimer and Van Lanschot Kempen acted as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris announces $150M ordinary shares offering
- Pharvaris’s Accelerated Phase 3 Trial Timeline and Market Potential Boost Buy Rating
- Pharvaris’s Promising Outlook: Accelerated Timeline and Market Potential for Deucrictibant in HAE Treatment
- Pharvaris Updates RAPIDe-3 Study Timeline for HAE Treatment
- Pharvaris to report topline Phase 3 results of deucrictibant in Q4